Neurocrine Biosciences
NBIX
396 hedge funds and large institutions have $8.66B invested in Neurocrine Biosciences in 2021 Q3 according to their latest regulatory filings, with 35 funds opening new positions, 138 increasing their positions, 156 reducing their positions, and 44 closing their positions.
146% more call options, than puts
Call options by funds: $89.4M | Put options by funds: $36.3M
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
3% less capital invested
Capital invested by funds: $8.9B → $8.66B (-$240M)
1.35% less ownership
Funds ownership: 96.71% → 95.35% (-1.4%)
3% less funds holding
Funds holding: 409 → 396 (-13)
12% less repeat investments, than reductions
Existing positions increased: 138 | Existing positions reduced: 156
20% less first-time investments, than exits
New positions opened: 35 | Existing positions closed: 44
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$117M |
| 2 |
EVM
Eaton Vance Management
Boston,
Massachusetts
|
+$61.7M |
| 3 |
DM
Deerfield Management
New York
|
+$39.4M |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$36.4M |
| 5 |
Millennium Management
New York
|
+$34.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$72.4M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$72.1M |
| 3 |
Capital International Investors
Los Angeles,
California
|
-$63.2M |
| 4 |
Rockefeller Capital Management
New York
|
-$56.6M |
| 5 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$54M |
NBIX Hedge Fund Activity: Q3 2021 in Review
396 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q3 2021, worth a combined $8.66B — down 2.7% from $8.9B a quarter earlier.
Sellers outnumbered buyers: 44 funds closed out of NBIX and 35 opened new positions — a net loss of 9 holders — while 156 trimmed existing stakes and 138 added.
The largest buyer was JP Morgan Chase, adding an estimated $117M. The largest seller was Invesco, cutting an estimated $72.4M.
- 396 institutional investors held Neurocrine Biosciences (NBIX) as of Q3 2021, down from 409 in Q2 2021.
- Funds reported $8.66B of Neurocrine Biosciences stock for Q3 2021, down 2.7% quarter-over-quarter.
- 35 funds opened new Neurocrine Biosciences positions in Q3 2021 and 44 closed out, a net change of -9 holders.
- The largest Neurocrine Biosciences buyer in Q3 2021 was JP Morgan Chase, an estimated $117M added.
- The largest Neurocrine Biosciences seller in Q3 2021 was Invesco, an estimated $72.4M sold.
Based on aggregated 13F filings for Q3 2021.